These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31625972)

  • 21. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
    Russ H; Mihatsch W; Gerlach M; Riederer P; Przuntek H
    Neurosci Lett; 1991 Feb; 123(1):115-8. PubMed ID: 1712088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects.
    van Vliet SA; Vanwersch RA; Jongsma MJ; van der Gugten J; Olivier B; Philippens IH
    Behav Pharmacol; 2006 Sep; 17(5-6):453-62. PubMed ID: 16940766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
    Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The comparison of neurobehavioral changes and impaired locations between the mouse model of manganism and Parkinson's disease].
    Dou CS; Zhi CN; Liu WL; Fu JL; Yao BY
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2018 Feb; 36(2):84-90. PubMed ID: 29699003
    [No Abstract]   [Full Text] [Related]  

  • 27. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primate models of Parkinson's disease.
    Collier TJ; Steece-Collier K; Kordower JH
    Exp Neurol; 2003 Oct; 183(2):258-62. PubMed ID: 14552866
    [No Abstract]   [Full Text] [Related]  

  • 30. MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yamaguchi H; Kajitani K; Dan Y; Furuichi M; Ohno M; Sakumi K; Kang D; Nakabeppu Y
    Cell Death Differ; 2006 Apr; 13(4):551-63. PubMed ID: 16273081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profile of acupuncture treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease model.
    Hong MS; Park HK; Yang JS; Park HJ; Kim ST; Kim SN; Park JY; Song JY; Park HK; Jo DJ; Park SW; HwanYun D; Ban JY; Chung JH
    Neurol Res; 2010 Feb; 32 Suppl 1():74-8. PubMed ID: 20034450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset.
    Nomoto M; Fukuda T
    Neuropharmacology; 1993 May; 32(5):473-7. PubMed ID: 8321428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
    Close SP; Marriott AS; Pay S
    Br J Pharmacol; 1985 Jun; 85(2):320-2. PubMed ID: 3928007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease.
    McCollum M; Ma Z; Cohen E; Leon R; Tao R; Wu JY; Maharaj D; Wei J
    Mol Neurobiol; 2010 Jun; 41(2-3):410-9. PubMed ID: 20405343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Perry TL; Yong VW; Hansen S; Jones K; Bergeron C; Foulks JG; Wright JM
    J Neurol Sci; 1987 Nov; 81(2-3):321-31. PubMed ID: 3121800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
    Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
    Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
    Pifl C; Schingnitz G; Hornykiewicz O
    Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced neuroinflammation and oxidative stress are associated with altered hippocampal neurogenesis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mice.
    Singh S; Mishra A; Tiwari V; Shukla S
    Behav Pharmacol; 2019 Dec; 30(8):689-699. PubMed ID: 31703031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration.
    Quik M; Polonskaya Y; Gillespie A; K Lloyd G; Langston JW
    Neuroscience; 2000; 100(1):63-72. PubMed ID: 10996459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.